INNPF Stock — InnoCan Pharma Corporation

InnoCan Pharma Corporation (INNPF)

Updated October 15, 2026.

INNPF is a Stock. Its deepest 1-year drawdown was 89.5%.

InnoCan Pharma Corporation is a pharmaceutical technology company developing a cannabidiol-loaded liposome drug delivery platform targeting chronic pain management in human and veterinary applications, alongside topical pain-relief and cosmetic products. The company operates through online sales and other operations across the United States, Canada, Europe, and internationally. Distribution information is not currently available.

INNPF performance

Returns are updating. INNPF's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 89.5%.

INNPF key facts

Asset type

Stock

Asset class

Equity

Inception date

04/09/2019

Distribution frequency

None

Last close

$1.33 (as of 2026-10-15)

Market cap

$5,983,367

Average volume

200.0

Beta

0.297

Payout ratio

0.0%

EPS

$-0.26

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

INNPF risks and drawbacks

The deepest 1-year drawdown on record here is 89.5%.

Who may consider INNPF — and who may not

It is a weaker fit for investors who need monthly cash flow (INNPF does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on INNPF

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions